Key Financial Inc’s Neurocrine Biosciences NBIX Stock Holding History

Key Financial Inc’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.48K	Hold	34	–	–	﹤0.01%	1053
2025 Q4	$4.82K	Hold	34	–	–	﹤0.01%	1040
2025 Q3	$4.66K	Hold	34	–	–	﹤0.01%	1056
2025 Q2	$4.27K	Hold	34	–	–	﹤0.01%	1068
2025 Q1	$3.76K	Hold	34	–	–	﹤0.01%	1056
2024 Q4	$4.64K	Hold	34	–	–	﹤0.01%	1014
2024 Q3	$3.92K	Hold	34	–	–	﹤0.01%	1024
2024 Q2	$4.68K	Hold	34	–	–	﹤0.01%	974
2024 Q1	$4.69K	Hold	34	–	–	﹤0.01%	956
2023 Q4	$4.48K	Hold	34	–	–	﹤0.01%	964
2023 Q3	$3.83K	Hold	34	–	–	﹤0.01%	1003
2023 Q2	$3.21K	Buy	+34	New	+$3.32K	﹤0.01%	1094

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Key Financial Inc's NBIX Position: Q1 2026 in Review

Key Financial Inc held its Neurocrine Biosciences (NBIX) position steady in Q1 2026 at 34 shares worth $4.48K. The position accounts for ﹤0.01% of the portfolio, ranked #1053.

Key Financial Inc first reported a position in NBIX in Q2 2023 and has held it in 12 quarters since. The position peaked at $4.82K in Q4 2025. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

Key Financial Inc held 34 shares of Neurocrine Biosciences worth $4.48K as of Q1 2026.
Key Financial Inc left its Neurocrine Biosciences share count unchanged in Q1 2026.
Neurocrine Biosciences made up ﹤0.01% of Key Financial Inc's portfolio in Q1 2026, its #1053 holding.
Key Financial Inc first reported a position in Neurocrine Biosciences in Q2 2023 and has held it in 12 quarters since.
Key Financial Inc's Neurocrine Biosciences position peaked at $4.82K in Q4 2025.
694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Key Financial Inc's 13F filing for Q1 2026, filed 24 Apr 2026.